blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3126520

EP3126520 - AMG-337 FOR USE IN THE TREATMENT OF CANCERS HAVING A MET AMPLIFICATION [Right-click to bookmark this link]
Former [2017/06]BIOMARKERS AND USE OF MET INHIBITOR FOR TREATMENT OF CANCER
[2021/09]
StatusNo opposition filed within time limit
Status updated on  15.04.2022
Database last updated on 19.07.2024
FormerThe patent has been granted
Status updated on  10.05.2021
FormerGrant of patent is intended
Status updated on  15.02.2021
FormerExamination is in progress
Status updated on  30.08.2019
FormerRequest for examination was made
Status updated on  06.01.2017
FormerThe international publication has been made
Status updated on  01.11.2016
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
AMGEN, INC.
One Amgen Center Drive
Thousand Oaks, CA 91320 / US
[2017/06]
Inventor(s)01 / CAENEPEEL, Sean
2090 Stonehill Circle
Thousand Oaks, California 91360 / US
02 / COXON, Angela
11136 Broadview Drive
Moorpark, California 93021 / US
03 / DU, Zhiqiang
One Amgen Center Drive
Thousand Oaks, California 91320 / US
04 / HUGHES, Paul
909 14th Street, 1
Santa Monica, California 90403 / US
05 / LOBERG, Robert
2465 Rutland Place
Thousand Oaks, California 91362 / US
06 / NGARMCHAMNANRITH, Gift
One Amgen Center Drive
Thousand Oaks, California 91320 / US
07 / SABLE, Beate
1560 Newbury Road, 236
Newbury Park, California 91320 / US
 [2021/23]
Former [2017/09]01 / CAENEPEEL, Sean
2090 Stonehill Circle
Thousand Oaks, CA 91360 / US
02 / COXON, Angela
11136 Broadview Drive
Moorpark, CA 93021 / US
03 / DU, Zhiqiang
One Amgen Center Drive
Thousand Oaks, California 91320 / US
04 / HUGHES, Paul
909 14th Street, 1
Santa Monica, California 90403 / US
05 / LOBERG, Robert
2465 Rutland Place
Thousand Oaks, California 91362 / US
06 / NGARMCHAMNANRITH, Gift
One Amgen Center Drive
Thousand Oaks, California 91320 / US
07 / SABLE, Beate
1560 Newbury Road, 236
Newbury Park, California 91320 / US
Former [2017/06]01 / CAENEPEEL, Sean
5623 Faust Avenue
Woodland Hills, California 91367 / US
02 / COXON, Angela
12004 Bubbling Brook Street
Moorpark, California 93021 / US
03 / DU, Zhiqiang
One Amgen Center Drive
Thousand Oaks, California 91320 / US
04 / HUGHES, Paul
909 14th Street, 1
Santa Monica, California 90403 / US
05 / LOBERG, Robert
2465 Rutland Place
Thousand Oaks, California 91362 / US
06 / NGARMCHAMNANRITH, Gift
One Amgen Center Drive
Thousand Oaks, California 91320 / US
07 / SABLE, Beate
1560 Newbury Road, 236
Newbury Park, California 91320 / US
Representative(s)V.O.
P.O. Box 87930
Carnegieplein 5
2508 DH Den Haag / NL
[2017/06]
Application number, filing date15772358.603.04.2015
[2017/06]
WO2015US24306
Priority number, dateUS201461975487P04.04.2014         Original published format: US 201461975487 P
US201461993871P15.05.2014         Original published format: US 201461993871 P
[2017/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015154005
Date:08.10.2015
Language:EN
[2015/40]
Type: A1 Application with search report 
No.:EP3126520
Date:08.02.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 08.10.2015 takes the place of the publication of the European patent application.
[2017/06]
Type: B1 Patent specification 
No.:EP3126520
Date:09.06.2021
Language:EN
[2021/23]
Search report(s)International search report - published on:US08.10.2015
(Supplementary) European search report - dispatched on:EP18.01.2018
ClassificationIPC:A61K31/4375, A61P35/00, C12Q1/6886
[2021/09]
CPC:
A61K31/4375 (EP,US); A61P35/00 (EP); C12Q1/6886 (EP,US);
C12Q2600/106 (EP,US); C12Q2600/154 (EP,US); C12Q2600/158 (EP,US)
Former IPC [2017/46]A61K31/4375, A61P35/00, C12Q1/68
Former IPC [2017/06]C12Q1/68, A61K31/53, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/06]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:AMG-337 ZUR BEHANDLUNG VON KREBS MIT EINER AMPFLIZIERUNG VON MET[2021/09]
English:AMG-337 FOR USE IN THE TREATMENT OF CANCERS HAVING A MET AMPLIFICATION[2021/09]
French:AMG-337 DESTINÉ AU TRAITEMENT DES CANCERS AYANT UNE AMPLIFICATION DE MET[2021/09]
Former [2017/06]BIOMARKER UND VERWENDUNG DES MET-INHIBITORS ZUR BEHANDLUNG VON KREBS
Former [2017/06]BIOMARKERS AND USE OF MET INHIBITOR FOR TREATMENT OF CANCER
Former [2017/06]BIOMARQUEURS ET UTILISATION DE L'INHIBITEUR DE MET DANS LE TRAITEMENT DU CANCER
Entry into regional phase01.11.2016National basic fee paid 
01.11.2016Search fee paid 
01.11.2016Designation fee(s) paid 
01.11.2016Examination fee paid 
Examination procedure01.11.2016Examination requested  [2017/06]
01.11.2016Date on which the examining division has become responsible
08.08.2018Amendment by applicant (claims and/or description)
03.09.2019Despatch of a communication from the examining division (Time limit: M06)
24.02.2020Reply to a communication from the examining division
18.06.2020Despatch of a communication from the examining division (Time limit: M04)
29.09.2020Reply to a communication from the examining division
16.02.2021Communication of intention to grant the patent
03.05.2021Fee for grant paid
03.05.2021Fee for publishing/printing paid
03.05.2021Receipt of the translation of the claim(s)
Opposition(s)10.03.2022No opposition filed within time limit [2022/20]
Fees paidRenewal fee
28.07.2017Renewal fee patent year 03
23.04.2018Renewal fee patent year 04
23.04.2019Renewal fee patent year 05
27.04.2020Renewal fee patent year 06
29.04.2021Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
30.04.201703   M06   Fee paid on   28.07.2017
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.04.2015
AL09.06.2021
AT09.06.2021
CY09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
ES09.06.2021
FI09.06.2021
HR09.06.2021
IT09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
MK09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
[2024/22]
Former [2024/20]HU03.04.2015
AL09.06.2021
AT09.06.2021
CY09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
ES09.06.2021
FI09.06.2021
HR09.06.2021
IT09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2024/18]HU03.04.2015
AL09.06.2021
AT09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
ES09.06.2021
FI09.06.2021
HR09.06.2021
IT09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2023/06]AL09.06.2021
AT09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
ES09.06.2021
FI09.06.2021
HR09.06.2021
IT09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/36]AL09.06.2021
AT09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
ES09.06.2021
FI09.06.2021
HR09.06.2021
IT09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/29]AL09.06.2021
AT09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
ES09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/26]AL09.06.2021
AT09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
ES09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/21]AT09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
ES09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/10]AT09.06.2021
CZ09.06.2021
EE09.06.2021
ES09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/09]AT09.06.2021
CZ09.06.2021
ES09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
PT11.10.2021
Former [2022/08]AT09.06.2021
CZ09.06.2021
ES09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
RS09.06.2021
SE09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
Former [2022/07]AT09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
RS09.06.2021
SE09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
Former [2021/51]FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
RS09.06.2021
SE09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
Former [2021/49]FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
SE09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
Former [2021/47]FI09.06.2021
LT09.06.2021
BG09.09.2021
Former [2021/46]FI09.06.2021
LT09.06.2021
Documents cited:Search[E]WO2016044772  (ARAXES PHARMA LLC [US]) [E] 1-13 * abstract * * page 27, line 25 - page 28, line 12 * * page 29, line 15 - line 18 * * page 31, line 17 - page 34, line 27 * * claims 1-49 *;
 [AD]  - JOCHEN K. LENNERZ ET AL, "MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib", JOURNAL OF CLINICAL ONCOLOGY, US, (20111220), vol. 29, no. 36, doi:10.1200/JCO.2011.35.4928, ISSN 0732-183X, pages 4803 - 4810, XP055412139 [AD] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1200/JCO.2011.35.4928
 [T]  - P. E. HUGHES ET AL, "In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models", MOLECULAR CANCER THERAPEUTICS, US, (20160419), vol. 15, no. 7, doi:10.1158/1535-7163.MCT-15-0871, ISSN 1535-7163, pages 1568 - 1579, XP055340933 [T] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-15-0871
International search[Y]US2006246492  (HABER DANIEL A [US], et al) [Y] 2-12, 14, 15, 17 * ; paragraphs [0010], [0029]-[0040], [0104], [0116] *;
 [XY]US8198448  (ALBRECHT BRIAN K [US], et al) [X] 1, 13, 16 * ; column 28, lines 21-26; column 379, lines 31-67 to column.380, lines 1-30; Claims 21, 37, 38 * [Y] 2-12, 14, 15, 17;
 [A]WO2013007808  (TRASLATIONAL CANCER DRUGS PHARMA S L [ES], et al) [A] 1-17 * ; abstract *;
 [A]WO2013120018  (POPULATION DIAGNOSTICS INC [US], et al) [A] 1-17 * ; abstract *;
 [Y]US2013225424  (BACUS SARAH S [US]) [Y] 11, 12 * ; paragraphs [0005]-[0011] *;
 [A]  - WANG, SY et al., "SU 5416 Is A Potent Inhibitor Of Hepatocyte Growth Factor Receptor (c-Met) And Blocks HGF-Induced Invasiveness Of Human Hepg2 Hepatoma Cells.", J Hepatol., (20040800), vol. 41, no. 2, pages 267 - 273, XP025958289 [A] 1-17 * ; DOI: 16.1016/j.jhep.2004.04.013. *

DOI:   http://dx.doi.org/10.1016/j.jhep.2004.04.013
 [A]  - XU, C et al., "Expression Of The c-Met Oncogene By Tumor Cells Predicts A Favorable Outcome In Classical Hodgkin's Lymphoma.", Haematologica., (20120400), vol. 97, no. 4, pages 572 - 578, XP055229997 [A] 1-17 * ; DOI: 10.3324/haematol.2011.056101. *

DOI:   http://dx.doi.org/10.3324/haematol.2011.056101
by applicantUS5470705
 US5514543
 WO9617958
 US5580732
 US5624800
 US5807682
 US6232068
 US6395486
 US2003190646
 US6734296
 US6756204
 US6759202
 US2005272083
 WO2007001868
 US8198448
    - JEMAL, A. et al., "Cancer statistics", CA Cancer J Clin, (20070000), vol. 57, pages 43 - 46
    - MERRY, A. et al., Gut, (20070000), vol. 56, pages 1503 - 1511
    - LENNERZ, J. K. et al., J. Clin. Oncol., (20110000), vol. 29, pages 1 - 8
    - PETERS, S. et al., Nat. Rev. Clin. Oncol., (20120000), vol. 9, pages 314 - 326
    - THERASSE et al., "New Guidelines to Evaluate the Response to Treatment in Solid Tumors", J. Natl. Cancer Inst., (20000200), vol. 92, no. 3, pages 205 - 216
    - PARK et al., Proc. Natl. Acad. Sci. USA, (19870000), vol. 84, pages 6379 - 83
    - "GenBank", Database accession no. NM _| 004985
    - "NCBI", Database accession no. NG 008996.1
    - "Clinical Proteomics: Methods and Protocols", Methods in Molecular Biology, (20080000), vol. 428
    - POLLACK et al., Nat. Genet., (19990000), vol. 23, no. 1, pages 41 - 6
    - PASTINEN, Genome Res, (19970000), vol. 7, page 606614
    - JACKSON, Nature Biotechnology, (19960000), vol. 14, page 1685
    - CHEE, Science, (19950000), vol. 274, page 610
    - PINKEL et al., Nature Genetics, (19980000), vol. 20, pages 207 - 211
    - Nat Biotechnol, (20080300), vol. 26, no. 3, pages 293 - 4
    - ANGERER, Meth. Enzymol., (19870000), vol. 152, page 649
    - WUWALLACE, Genomics, (19890000), vol. 1-3, page 560
    - BARRINGER et al., Gene, (19900000), vol. 89, page 117
    - GIBSON et al., Genome Research, (19960000), vol. 6, pages 986 - 1001
    - GIBSON et al., Genome Res, (19960000), vol. 10, pages 986 - 1001
    - LANDEGREN et al., Science, (19880000), vol. 241, page 1077
    - KWOH et al., Proc. Natl. Acad. Sci. USA, (19890000), vol. 86, page 1173
    - GUATELLI et al., Proc. Nat. Acad. Sci. USA, (19900000), vol. 87, page 1874
    - SCHIMANSKI et al., Cancer Res, (19990000), vol. 59, pages 5169 - 5175
    - NAGASAKA et al., J. Clin. Oncol., (20040000), vol. 22, pages 4584 - 4596
    - LIEVRE et al., Cancer Res, (20060000), vol. 66, pages 3992 - 3994
    - THERASSE et al., J. Natl. Cancer Inst., (20000000), vol. 92, no. 3, pages 205 - 216
    - MACDONALD D.R. et al., J Clin Oncol, (19900000), vol. 8, pages 1277 - 1280
    - CAPUZZO et al., J. Nat. Cancer Inst., (20050000), vol. 97, no. 9, pages 643 - 655
    - CAPUZZO et al., Brit. J. of Cancer, (20080000), vol. 99, pages 83 - 89
    - DAVIS et al., Nat. Biotechnol., (20110000), vol. 29, pages 1046 - 1057
    - FABIAN et al., Nat. Biotechnol., (20050000), vol. 23, pages 329 - 336
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.